Uterine Leiomyoma (Uterine Fibroids) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Uterine Leiomyoma (Uterine Fibroids) – Drugs In Development, 2024 report and make more profitable business decisions.
Uterine leiomyoma, also known as uterine fibroids, are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods (seven days or more of menstrual bleeding), pelvic pressure or pain, frequent urination, difficulty emptying the bladder, constipation, and backache or leg pain.
The Uterine Leiomyoma (Uterine Fibroids) drugs in development market research report provide comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Uterine Leiomyoma (Uterine Fibroids) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Uterine Leiomyoma (Uterine Fibroids) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Uterine Leiomyoma (Uterine Fibroids) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Uterine Leiomyoma (Uterine Fibroids) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncASKA Pharmaceutical Holdings Co Ltd
Bio Genuine
Daewon Pharmaceutical Co Ltd
Eurofarma Laboratorios SA
Evestra Inc
Foresee Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Northwestern University
Shijiazhuang Yiling Pharmaceutical Co Ltd
Synmosa Biopharma Corp
TiumBio Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Uterine Leiomyoma (Uterine Fibroids) reports